MP60-01 PREVALENCE OF NON-RECOMMENDED SCREENING FOR PROSTATE CANCER AND BREAST CANCER IN THE UNITED STATES

Abstract

You have accessJournal of UrologyProstate Cancer: Detection and Screening II1 Apr 2015MP60-01 PREVALENCE OF NON-RECOMMENDED SCREENING FOR PROSTATE CANCER AND BREAST CANCER IN THE UNITED STATES Firas Abdollah, Jesse Sammon, Akshay Sood, Dane Klett, Daniel Pucheril, Paul Nguyen, Toni Choueiri, Adam Kibel, Mark Preston, Mani Menon, Joel Weissman, and Quoc-Dien Trinh Firas AbdollahFiras Abdollah More articles by this author , Jesse SammonJesse Sammon More articles by this author , Akshay SoodAkshay Sood More articles by this author , Dane KlettDane Klett More articles by this author , Daniel PucherilDaniel Pucheril More articles by this author , Paul NguyenPaul Nguyen More articles by this author , Toni ChoueiriToni Choueiri More articles by this author , Adam KibelAdam Kibel More articles by this author , Mark PrestonMark Preston More articles by this author , Mani MenonMani Menon More articles by this author , Joel WeissmanJoel Weissman More articles by this author , and Quoc-Dien TrinhQuoc-Dien Trinh More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2203AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Given that the harms of prostate (PCa) and breast (BCa) cancer screening may outweigh the benefits for individuals with limited life expectancy, current guidelines do not recommend screening in these individuals. However, there is limited nationwide data addressing the prevalence of non-recommended screening for PCa and BCa. The objective of this study is to estimate the US nationwide, and state-by-state prevalence of non-recommended PCa and BCa screening in individuals with a life expectancy<10 years. METHODS A cohort of 150,452 individuals aged ≥65 years (weighted population size of 43.857 million) who responded to the 2012 Behavioral Risk Factor Surveillance System survey. Published life tables relying on age, sex, race, and comorbidity were used to calculate life expectancy. The main outcome measure is self-reported prostate specific antigen (PSA) test (without history of prostate cancer/problems) or mammogram within the past year. RESULTS Overall, 16.3% of individuals aged 65 and older underwent non-recommended PSA or mammography screening (based on a life expectancy of <10 years). This represents 32.1% of the individuals aged 65 and older who were screened. At adjusted analysis, the prevalence of non-recommended screening was higher in older (OR: 1.11; 95%CI: 1.10-1.11), and in Black (OR: 1.27, 95%CI: 1.11-1.46) individuals. Conversely, it was lower in females (OR: 0.63; 95%CI: 0.59-0.67). Likewise, individuals without access to a health care provider (0.43; 95%CI: 0.36-0.51) or who lacked health insurance (OR: 0.47; 95%CI: 0.36-0.61) were less likely to receive non-recommended screening. Significant state-by-state variation in non-recommended screening was observed, especially for PCa. CONCLUSIONS Non-recommended screening is reported in nearly one out of three screened individuals aged ≥65 years, and varies significantly by state. The prevalence of non-recommended screening is higher for PCa than for BCa screening (higher in male than females). Policy should be directed to incentivize appropriate use of screening tests, which could lead to more cost-efficient utilization of health care resources. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e738 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Firas Abdollah More articles by this author Jesse Sammon More articles by this author Akshay Sood More articles by this author Dane Klett More articles by this author Daniel Pucheril More articles by this author Paul Nguyen More articles by this author Toni Choueiri More articles by this author Adam Kibel More articles by this author Mark Preston More articles by this author Mani Menon More articles by this author Joel Weissman More articles by this author Quoc-Dien Trinh More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...